Cellid: Material Event Report (Decision on Capital Increase)

Decision to issue ₩3bn in third-party allocated paid-in capital increase for working capital

Key figures: New share issue price ₩2,250, total proceeds approx. ₩3bn

An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).

Cellid, an immuno-oncology developer, declined due to supply-demand deterioration from foreign selling, despite expectations for technology transfers and clinical progress.

Despite positive momentum in the immuno-oncology sector, Cellid shares fell 9.19% as foreign investors sold approximately 62,000 shares. No specific negative disclosures were identified, suggesting the decline was driven by foreign selling pressure outweighing retail buying.

• 09.22 ★★★★ Strengthening management control through third-party paid-in capital increase and change in largest shareholder
• 09.22 ★★ [Amendment] Material Fact Report (Decision on Paid-in Capital Increase)
• 09.21 ★★★★★ Change in management control and new investment attraction via third-party paid-in capital increase